Filing Details

Accession Number:
0000899243-19-026595
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-04 17:51:26
Reporting Period:
2019-11-04
Accepted Time:
2019-11-04 17:51:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1720725 Oyster Point Pharma Inc. OYST () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1228684 Phd J William Link C/O Oyster Point Pharma, Inc.
202 Carnegie Center, Suite 109
Princeton NJ 08540
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Acquisiton 2019-11-04 10,420 $0.00 12,438 No 4 C Indirect See footnotes
Common Stock, Par Value $0.001 Per Share Acquisiton 2019-11-04 1,654,359 $0.00 1,974,798 No 4 C Indirect See footnotes
Common Stock, Par Value $0.001 Per Share Acquisiton 2019-11-04 27,500 $16.00 2,002,298 No 4 P Indirect See footnotes
Common Stock, Par Value $0.001 Per Share Acquisiton 2019-11-04 955,392 $0.00 955,392 No 4 C Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
No 4 C Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.001 Per Share Series A Convertible Preferred Stock Disposition 2019-11-04 10,420 $0.00 10,420 $0.00
Common Stock, Par Value $0.001 Per Share Series A Convertible Preferred Stock Disposition 2019-11-04 1,654,359 $0.00 1,654,359 $0.00
Common Stock, Par Value $0.001 Per Share Series B Convertible Preferred Stock Disposition 2019-11-04 955,392 $0.00 955,392 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  2. Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV").
  3. Shares held by Versant Venture Capital IV, L.P. ("Versant IV").
  4. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  5. Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C.